Recruiting

MyCondro™

Sponsor:

Lesaffre International

Code:

NCT07493239

Conditions

Joint Health

Eligibility Criteria

Sex: All

Age: 45+

Healthy Volunteers: Accepted

Interventions

MyCondro 300mg

MyCondro 600mg

Study Details

Brief summary:

This study evaluates the effect of two different doses of a consumer-grade product, MyCondro™, on individuals experiencing mobility issues related to knee osteoarthritis. The primary goal is to measure improvements in overall joint health and mobility by tracking changes in participants' total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scores from the beginning to the end of the trial. Additionally, the study aims to assess secondary outcomes, including the product's impact on pain, stiffness, knee function, patient-reported improvement, inflammatory blood markers (CRP), and daily physical activity.

Conditions

Joint Health

Study ID

NCT07493239

Start date

Mar 4, 2026

Status verified date

Mar, 2026

Completion date

Nov 2, 2026

Anticipated

Primary completion date

Oct 5, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 45+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Individuals age 45 years and older.
  • BMI range between 18-35 kg/m².
  • Self-reported mobility issues, including mobility impairment and joint discomfort associated with a known diagnosis of Knee Osteoarthritis. This impairment and discomfort must have persisted for at least 6 months prior to randomization and have been actively experienced within the last 3 months.
  • Willingness to avoid high Chondroitin Sulfate-containing foods (i.e., animal cartilages, bones, or derivatives such as gelatin) for the duration of the study period.
  • Willingness to refrain from supplements containing Chondroitin Sulfate for the duration of the study period.
  • Able to read and understand English.
  • Able to read, understand, and provide informed consent.
  • Able to use a personal smartphone device and download the Chloe by People Science app.
  • Able to receive shipments of the product at an address within the United States.
  • Able to complete study assessments over the course of up to 16 weeks.

Exclusion Criteria:

Any potential participants will be excluded if they meet any of the following criteria:

  • Technology Limitation: Do not have a personal smartphone, lack internet access, or are unwilling to download the Chloe app.
  • Concomitant Therapies

1. Use of a Chondroitin Sulfate supplement in the 3 months prior to randomization.
2. Current use of other joint health supplements (e.g., glucosamine, hyaluronic acid, collagen peptides) for at least 4 weeks prior to randomization.
3. Use of any intra-articular or intravenous steroid injections in the last 3 months.
4. Receiving any investigational therapies or treatments within 30 days prior to randomization.

Other Illnesses or Conditions

1. Self-reported inflammatory arthropathies, such as Rheumatoid Arthritis, Gout, and Infectious Arthritis.
2. Significant systemic lung, liver, heart, or kidney disease (excluding hypertension).
3. Prior history of knee surgery within 3 months preceding the study period, or planned knee surgery (including arthroscopy) during the study period.
4. Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder.
5. Currently pregnant, planning to become pregnant in the next 20 weeks, or breastfeeding.
6. Presence of a knee prosthesis.
7. Any significant illness, disease, or condition which, in the opinion of the Principal Investigator, may impact the ability to participate in the study or impact the study outcomes.

Allergies and Intolerances

1. Known hypersensitivity or previous allergic reaction to: Chondroitin sulfate, Maltodextrin, Mannitol, Magnesium Stearate, Silicon dioxide, Microcrystalline cellulose, or Talc.
2. Known sensitivity or intolerance to wheat or gluten.

General Compliance

1- Unlikely for any reason to be able to comply with the trial, or considered unsuited for participation in the study by the Principal Investigator.

Study Design

Enrollment

240 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: 300 mg

Participants in this arm will receive a 300 mg daily dose of the supplement, administered as two capsules every morning after breakfast for a 12-week period

experimental: 600 mg

Participants in this arm will receive a 600 mg daily dose of the supplement, administered as two capsules every morning after breakfast for a 12-week period

Interventions

MyCondro 300mg

This is a non-animal Chondroitin sulfate formulation.

MyCondro 600mg

This is a non-animal Chondroitin sulfate formulation.

Primary outcome measure

  • MyCondro's effectiveness [ Time Frame: 12 weeks ]

Central Contacts and Locations

Central contacts

Locations

People Science

Recruiting

Los Angeles, California, United States, 90045

Contacts

Principal Investigator:

Noah Craft, MD, PhD

More Information

Sponsor

Lesaffre International

Last update posted

Jul 22, 2026

Last verified

Mar, 2026

Keywords

  • MyCondro, Gnosis, PS24
  • Joint function
  • Joint mobility
  • non-animal chondroitin sulfate

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Lesaffre International on 2026-07-22.